Alshowair Abdulmajeed, Altamimi Saleh, Alruhaimi Faisal A, Alshahrani Saad, Alsuwailem Fatima, Alkhaldi Mona, Abdalla Haiam, Alkhuraiji Fahad Hamad, Alaqeel Montaser Saad, Almureef Salman Sulaiman, Alhawasy Salman, Abdel-Azeem Amro
Community Health Excellence, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Academic and Training Affairs, Riyadh First Health Cluster Ministry of Health, Riyadh, Saudi Arabia.
Clinicoecon Outcomes Res. 2024 Apr 4;16:211-223. doi: 10.2147/CEOR.S451739. eCollection 2024.
This study aims to predict the expected cost savings associated with implementing a multidisciplinary team (MDT) approach to reduce macrovascular and microvascular complications among patients with type 2 diabetes mellitus (T2DM).
This economic evaluation study was conducted in Riyadh First Health Cluster, Saudi Arabia as a predictive model conceptualized by the authors based on models used in previous studies, particularly the CORE Diabetes Model. Our model was designed based on 1) the level of glycemic control among 24,755 T2DM patients served by MDTs; 2) the expected incidence of diabetes-related complications without intervention; 3) the predicted risk reduction of developing diabetes-related complications with MDTs. Costs of complications and cost savings were then calculated and expressed as mean incremental annual cost savings adjusted for a 1% reduction in HbA1c, and a 10 mmHg reduction in systolic blood pressure (SBP).
Along with the expected reduction in all diabetes-related complications, the average incremental cost savings per diabetic patient is predicted to be ($38,878) with approximately ($11,108) in the year of complication onset and ($27,770) over the subsequent post-index 10-years. On adjustment of cost savings, the average incremental cost savings are predicted to be ($22,869) for each 1% reduction in HbA1c per diabetic patient and ($27,770) for every 10 mmHg reduction in SBP per diabetic patient.
MDT as a model of care is effective in glycemic control among T2DM patients with a predicted significant reduction of all diabetes-related complications and in turn, a predicted significant cost savings.
本研究旨在预测实施多学科团队(MDT)方法以减少2型糖尿病(T2DM)患者大血管和微血管并发症所带来的预期成本节约。
这项经济评估研究在沙特阿拉伯利雅得第一健康集群进行,是作者基于先前研究中使用的模型,特别是CORE糖尿病模型概念化的预测模型。我们的模型基于以下因素设计:1)MDT服务的24,755名T2DM患者的血糖控制水平;2)无干预情况下糖尿病相关并发症的预期发生率;3)MDT降低糖尿病相关并发症发生风险的预测值。然后计算并发症成本和成本节约,并表示为糖化血红蛋白(HbA1c)降低1%和收缩压(SBP)降低10 mmHg调整后的平均年度增量成本节约。
随着所有糖尿病相关并发症的预期减少,预计每位糖尿病患者的平均增量成本节约为(38,878美元),并发症发作当年约为(11,108美元),后续索引后10年为(27,770美元)。调整成本节约后,预计每位糖尿病患者HbA1c每降低1%的平均增量成本节约为(22,869美元),SBP每降低10 mmHg的平均增量成本节约为(27,770美元)。
MDT作为一种护理模式在T2DM患者的血糖控制方面有效,预计所有糖尿病相关并发症将显著减少,进而预计可显著节约成本。